Seagen, A Wholly Owned Subsidiary Of Pfizer
Clinical trials sponsored by Seagen, A Wholly Owned Subsidiary Of Pfizer, explained in plain language.
-
New combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a combination of brentuximab vedotin and standard chemotherapy (CHP) in 82 people with a rare type of lymphoma called peripheral T-cell lymphoma (PTCL) that has low levels of a protein called CD30. The goal was to see how well the treatment shrank or eliminated …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
New cancer drug SGN-B6A tested in chinese patients – safety first
Disease control CompletedThis early-stage trial tested the safety of a drug called sigvotatug vedotin (SGN-B6A) in 6 Chinese patients with advanced solid tumors like lung, head and neck, and stomach cancers. The main goal was to see what side effects occur and how the body processes the drug. This is not…
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control CompletedThis study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. The trial included 161 participants and measured how many saw their tumors shrink. It al…
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC